Skip to main content

Table 1 The clinic-pathologic characteristics of luminal B HER2-negative breast cancer

From: Prognostic values of negative estrogen or progesterone receptor expression in patients with luminal B HER2-negative breast cancer

  ER and PR positive
N = 160 (%)
ER or PR negative
N = 24 (%)
p value
Age (years) median 48.5 55.5 0.0336
 = or <45 59 (36.9) 3 (12.5)
 >45 101 (62.1) 21 (87.5)
TNM stage (AJCC 8th)    0.1061
 I 50 (31.2) 5 (20.8)
 II 81 (50.6) 11 (45.8)
 III 27 (16.9) 6 (25.0)
 IV 2 (1.3) 2 (8.3)
Breast operation    0.8761
 BCS 113 (70.6) 16 (66.7)
 Mastectomy 47 (29.4) 8 (33.3)
Axillary node operation    0.2088
 SLNB 63 (39.4) 7 (29.2)
 ALND 96 (60.0) 16 (66.7)
 omit 1 (0.6) 1 (4.2)
Histologic type    0.1587
 Invasive ductal carcinoma 142 (88.8) 22 (91.7)
 Invasive Lobular carcinoma 5 (3.1) 2 (8.3)
 Mucinous carcinoma 6 (3.8) 0 (0)
 Papillary carcinoma 6 (3.8) 0 (0)
 Micropapillary carcinoma 3 (1.9) 0 (0)
 Apocrine carcinoma 1 (0.3) 0 (0)
Histologic grade    0.4421
 II 31 (19.4) 8 (33.3)
 III 101 (63.1) 16 (66.7)
 Not available 28 (17.5) 0 (0)
Nuclear grade    0.9403
 I 82 (51.2) 14 (58.3)
 II 45 (28.1) 9 (37.5)
 III 5 (3.1) 1 (4.2)
 Not available 28 (17.5) 0 (0)
Number of tumor    0.6269
 Single 137 (85.6) 22 (91.7)
 Multiple 23 (14.4) 2 (8.3)
Bcl-2 expression    0.0006
 = or <10 % 17 (10.9) 11 (39.3)
 >10 % 139 (89.1) 17 (60.7)
Ki 67    0.0167
 = or <50 % 136 (85.0) 15 (62.5)
 >50 % 24 (15.0) 9 (37.5)
Adjuvant therapy
 Chemotherapy
  Yes 133 (83.1) 22 (91.7) 0.1321
  Anthracycline/taxane based 72 (45.0) 17 (70.8)
  CMF or CNF based 50 (36.9) 5 (20.7)
  No 27 (16.9) 2 (8.3)
 Hormonal therapy
  Yes 148 (92.5) 22 (91.7) 0.0579
  SERM 100 (62.5) 9 (37.5)
  AI 49 (30.6) 13 (54.2)
  No 11 (6.9) 2 (8.3)
 Radiation therapy
  Yes 110 (68.7) 17 (70.8) 0.9752
  No 50 (31.2) 7 (29.2)
  1. TNM tumor size/node/metastasis, AJCC American Joint Committee on Cancer, BCS breast conserving surgery, SLNB sentinel lymph node biopsy, ALND axillary lymph node dissection, SERM selective estrogen receptor modulator, AI aromatase inhibitor, CMF cyclophosphamide/methotrexate/5-fluorouracil, CNF cyclophosphamide/vinorelbine/5-fluorouracil